GlassScriptPhysician profile
Chad M Toups
NPI 1336224047
$2,979.83
in general payments reported to CMS, 2019-2025
18 companies · $581 in 2025
The $581 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $250 · 2021: $35.74 · 2022: $73.58 · 2023: $1,038 · 2024: $244 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $499.70 | 2019-2025 | Precision 1, Clareon, Total30 |
| Coopervision INC. | $369.49 | 2019-2023 | Biofinity Contact Lens |
| Glaukos Corporation | $329.71 | 2025 | Photrexa Viscous and Photrexa |
| Johnson & Johnson Vision Care, INC. | $308.83 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $273.79 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $225.88 | 2023 | Cequa |
| Oyster Point Pharma, INC. | $139.24 | 2023 | Tyrvaya |
| Abbvie INC. | $133.60 | 2023 | Vuity |
| Tarsus Pharmaceuticals, INC. | $123.35 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $119.38 | 2022-2025 | Infuse |
| Lkc Technologies, INC. | $119.20 | 2023 | |
| Optos, INC. | $105.18 | 2019 | |
| Genzyme Corporation | $94.87 | 2019 | |
| Biotissue Holdings INC. | $38.31 | 2022 | |
| Dompe US, INC. | $33.52 | 2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare Solutions, INC. | $28.75 | 2019 | |
| Astellas Pharma US INC | $20.97 | 2024 | Izervay |
| Allergan, INC. | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Toups listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.